FST and ovarian carcinoma: BRCA1 may induce its cytoprotective effect via modulating the expression of both SMAD6 and FST [69], and in turn, may induce BMP signaling pathways, which may then inhibit or delay the progression of ovarian cancer, specifically epithelial-origin ovarian cancer.